2023
Can peripheral psychophysiological markers predict response to exposure-based cognitive behavioral therapy in youth with severely impairing irritability? A study protocol
Grasser L, Erjo T, Goodwin M, Naim R, German R, White J, Cullins L, Tseng W, Stoddard J, Brotman M. Can peripheral psychophysiological markers predict response to exposure-based cognitive behavioral therapy in youth with severely impairing irritability? A study protocol. BMC Psychiatry 2023, 23: 926. PMID: 38082431, PMCID: PMC10712194, DOI: 10.1186/s12888-023-05421-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAngerCognitive Behavioral TherapyFemaleHumansIrritable MoodMaleResearch DesignTreatment OutcomeConceptsExposure-based cognitive-behavioral therapyCognitive behavioral therapyPhysiological arousalBehavioral therapyAffective Reactivity IndexMultiple baseline trialClinical Global Impression ScaleAnger-inducing stimuliPeripheral physiological indicatorsIndividual differencesPsychophysiological markersPerson changesExposure sessionsMultilevel modelingPsychophysiological indicatorsHR/HRVInitial evidenceMental healthReasons youthReactivity indexYouthAppropriate Institutional Review BoardTreatment mechanismsGlobal Impression ScaleCourse of treatment
2007
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang CY, Tseng WL, Allen AJ, Lee P. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2007, 17: 447-460. PMID: 17822340, DOI: 10.1089/cap.2006.0091.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic Uptake InhibitorsAppetiteAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityChildDouble-Blind MethodDrug Administration ScheduleFacultyFemaleHumansMaleNauseaParentsPropylaminesPsychiatric Status Rating ScalesSeverity of Illness IndexTaiwanTreatment OutcomeConceptsAttention-deficit/hyperactivity disorderPrimary efficacy measureEfficacy measuresDaily atomoxetineAdverse eventsADHD Rating Scale-IV-Parent VersionDrug-related serious adverse eventsHyperactivity disorderSecondary efficacy measuresSerious adverse eventsClinical Global ImpressionCarried-forward approachEnd of studyTreatment effect sizeAtomoxetine groupPlacebo groupTreat basisPediatric patientsGlobal ImpressionSafe treatmentClinical trialsInvestigator AdministeredEdition criteriaTreatment groupsMental disorders